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In this issue ofCancer Cell, Hao and colleagues report a non-canonical interaction between the insulin recep-
tor substrate 1 and certain oncogenic variants of the p110a catalytic subunit of phosphoinositide 3-kinase
(PI3K). A cell-penetrant peptide that disrupts this interaction downregulates PI3K signaling and inhibits tumor
growth in mice.More than 5,000 mutations of the p110a
catalytic subunit of class IA phosphoino-
sitide 3-kinase (PI3K) in cancers have
been reported, placing PIK3CA (the
gene encoding p110a) among the most
commonly mutated oncogenes. So far,
all mutations show gain-of-function,
leading to increased PI3K activity, sig-
naling, and cell transformation. These
mutations are widely distributed through-
out p110a, which has sparked the ques-
tion of whether there are any unifying
mechanisms for how these diverse muta-
tions activate PI3K. The activity of the
wild-type p110a is normally regulated by
the p85 regulatory subunit; a p85 SH2
domain associates with the helical
domain of p110a, thereby inhibiting the
enzyme’s basal activity (Figure 1A). Asso-
ciation of the N-terminal SH2 domain of
p85 with tyrosine phosphorylated YXXM
motifs in activated receptors or adaptor
proteins such as insulin receptor sub-
strate 1 (IRS1) disrupts this inhibitory
interaction.
The six isoforms of IRS (IRS1–6) are
adaptor proteins that are important for
regulating proliferation, metabolism, and
differentiation. IRSs are key mediators
of insulin receptor and insulin-like growth
factor-I receptor functions, and IRSs can
be phosphorylated on tyrosine residues
by insulin receptor. The canonical role
of IRS signaling involves phosphorylated
tyrosines (pY) in the C terminus of IRS1
recruiting SH2-domain containing pro-
teins (Taniguchi et al., 2006). Shortly after
its discovery more than 20 years ago
(Sun et al., 1991), it was shown that tyro-
sine phosphorylation of YXXM sites in
IRS1 results in its interaction with the
SH2 domains of the p85 regulatory sub-
unit of PI3Ks, accompanied by PI3K
activation. The consequence of p85
SH2 domains binding to pY in IRS1 isdisinhibition of p110a. IRS1 is required
for the transforming potential of many
oncogenes, and several studies have
shown that IRS1 overexpression can
result in transformation (Dearth et al.,
2007). IRS1 can also form many non-
canonical interactions that do not involve
binding to SH2 domains (Dearth et al.,
2007).
One subset of p110a mutations, typi-
fied by the hot spot E545K mutation
in the helical domain, increases PI3K
activity by circumventing the inhibitory
influence of the p85 regulatory subunit.
The p110a-E545K mutant cannot form
the inhibitory interaction with p85 (Miled
et al., 2007), so this mutant’s activity
in vitro resembles the activated wild-
type enzyme. In this issue of Cancer
Cell, Hao et al. (2013) asked whether
this disinhibition of p110a-E545K fully
explains its phenotype or whether there
might be extrinsic contributing factors.
They began by carrying out a proteomic
analysis to see if there might be part-
ners of p110a-E545K that are unique
to this mutant as compared with the
wild-type enzyme. They show that
p110a-E545K and several other onco-
genic p110a mutants form non-canoni-
cal interactions with IRS1 that are
independent of the p85 regulatory sub-
unit (Figures 1B and 1C) (Hao et al.,
2013). This unique p110a-E545K/IRS1
interaction also may be the reason that
a previous report based on targeted
mode mass spectrometry showed a
greater association of p110a-E545K
with IRS1 than the wild-type enzyme
(Yang et al., 2011).
The ability of mutations broadly distrib-
uted throughout the three-dimensional
structure of p110a to bind to IRS1
(Figure 1A) suggests that the non-canon-
ical interaction is not a simple contactCancer Celwith only the helical domain. This is remi-
niscent of the conundrum of how onco-
genic mutations distributed throughout
the structure of p110a all activate the
enzyme. Structural studies of oncogenic
variants of p110a have helped to answer
this question. These oncogenic muta-
tions cause allosteric changes mimicking
the dynamic events that accompany
activation of the wild-type enzyme (Burke
et al., 2012). Activation-associated allo-
steric changes are prominent in four
p110a regions: the ABD/RBD linker, the
C2/iSH2 interface, the helical domain,
and a region near the C terminus of the
enzyme. Hao et al. (2013) show that mu-
tants in the first three of these regions
lead to increased IRS1 association (Fig-
ures 1A and 1B). It may be that it is the
activated conformation of p110a that
associates with IRS1 so that many muta-
tions could lead to this same type of
IRS1 binding. However, Hao et al.
(2013) have so far examined the charac-
teristics of only the p110a-E545K mutant
in detail. Previous studies suggest that
this mutation causes conformational
changes in the helical domain, the C2/
iSH2 interface, and the ABD/RBD linker.
This might explain why Hao et al. (2013)
found that the C2 domain mutation
N345K and the ABD/RBD linker mutant
K111N also led to increased IRS1 asso-
ciation (Figure 1A). It will be interesting
to see if the consequences of other
p110a mutants binding IRS1 are the
same as for p110a-E545K, i.e., increased
PI3K signaling, membrane association,
and tumor volume (Figure 1C). More
work is needed to answer key questions
about this non-canonical IRS1 interac-
tion: why is it specific to the mutant
enzymes, and what is the extent of
the interface of the mutant enzymes
with IRS1?l 23, May 13, 2013 ª2013 Elsevier Inc. 559
Figure 1. Non-Canonical Activation of Oncogenic Mutants of PI3Ka
by IRS1
(A) Crystal structure of the nSH2 and iSH2 of p85 (blue) with p110a (gray) (Man-
delker et al., 2009), illustrating oncogenic mutants that induced (red) or did not
induce (yellow) IRS1 binding.
(B) Domain architecture of p110a and locations of mutants tested by Hao et al.
(2013) along with the location of inhibitory contacts between the p110a and
p85 subunits.
(C) Non-canonical activation of PI3Ka by IRS1 leads to increased downstream
signaling and enhanced tumor volume.
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the p110a/IRS1 interaction
increases association with
membranes in cells and in-
creases p110a stability, but
it is not clear if these directly
result in the increased PI3K
signaling. Although IRS1
and p110a-E545K associate
in vitro, this does not lead to
increased lipid kinase activity.
It may be that the activation of
PI3K signaling observed in
cells is caused by IRS1
stabilizing the p110a-E545K
mutant protein, or possibly
activation in cells requires the
participation of another IRS1
partner. Hao et al. (2013)
show that the p110a kinase
domain mutant H1047R does
not show increased associa-
tion with IRS1 in unstimulated
cells, suggesting that the
p110a-H1047R and p110a-
E545K mutants function via
different mechanisms. This is
consistent with observations
in cells and in xenografts
showing differential effects
of these mutations, with the
p110a-E545K expression re-
sulting in amore severemeta-
static phenotype (Pang et al.,
2009; Zhao and Vogt, 2008).
Similarly, structural analysis
suggests that the p110a-
H1047R mutation cannot
elicit the same allosteric
changes caused by p110a-
E545K. Instead, p110a-
H1047R causes conforma-
tional changes that are
restricted to the C-terminal
lobe of the kinase domain
(Burke et al., 2012).
Remarkably, Hao et al.
(2013) have shown that a
peptide corresponding to an
18-residue region from the
helical domain of p110a-
E545K decreases PI3K sig-
naling in cells. Their peptide
design includes a ‘‘staple’’
intended to stabilize the
helical conformation presentin the full-length enzyme structure.
As a bonus, this hydrophobic staple
also appears to enable the peptide to560 Cancer Cell 23, May 13, 2013 ª2013 Elsenter cells. Importantly, treating p110a-
E545K-driven tumors in mice with this
peptide reduces tumor growth, showingevier Inc.that it may be possible to
design therapeutic agents
that would specifically in-
hibit the p110a-E545K onco-
gene. The observation that
several distinct oncogenic
mutants show increased as-
sociation with IRS1 sug-
gests that the IRS1 is target-
ing a wider interface than
just the p110a-helical do-
main. Allosteric changes pro-
duced by these p110a
mutations may expose a
secondary epitope. Never-
theless, the success of the
mutant, stapled helix in block-
ing this interaction might
imply that more drug-like
therapeutic agents might
also be effective in selectively
inhibiting PI3K signaling by
targeting the non-canonical
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ERK pathway activation in cells expressing wild-type BRAF is a well-reported, clinically-relevant adverse ef-
fect of the otherwise impressive response of BRAFV600E-mutated melanomas to RAF inhibitors. In this issue
of Cancer Cell, Holderfield and colleagues show that RAF autoinhibition underpins this paradox, further
complicating therapeutic strategies centered around RAF.The addiction of cancers to driver onco-
proteins has been exploited in the design
of novel therapies for cancer treatment;
there have been numerous success stor-
ies in translating this approach to the
clinic. BRAFV600E is a founder, oncogenic
driver mutation detected in 50% of hu-
man malignant melanomas. Tumors
bearing this mutation are remarkably sen-
sitive to ATP competitive RAF kinase in-
hibitors, notably vemurafenib (PLX4032)
and dabrafenib (GSK2118436) (Flaherty
et al., 2010). Resistance to many targeted
therapies is associated with longer-term
treatment, and, although the initial
response to the drug is impressive,
certainly in the case of vemurafenib, resis-
tant tumors re-emerge after 2–18 months
of treatment.
Apart from acquired drug resistance,
the use of RAF inhibitors, unlike other tar-
geted agents, introduces an additional
confounding issue that arises due to
unique complexities of RAF regulation:
ERK pathway activation in cells bearing
oncogenic or normally activated RAS.
This phenomenon of ‘‘paradoxical activa-
tion’’ was initially reported in cancer cell
lines bearing RAS mutations and was
supported by data utilizing a mouse
model expressing kinase inactive BRAF
(Heidorn et al., 2010). Subsequently, the
phenomenon has been shown to accountfor the emergence of squamous cell car-
cinomas (SCCs), many of which bear
RAS mutations, in 15%–30% of vemura-
fenib-treated human melanoma patients
(Su et al., 2012). SCCs are not consid-
ered to be a threat to patients as they
are well differentiated, nonmetastatic,
and relatively easy to remove because
they arise on the skin. However, there is
always the concern (although not yet
proven) that drug treatment may accel-
erate progression of RAS-driven internal
lesions that are more difficult to detect.
Consequently, there has been a drive to
understand the mechanisms underpin-
ning ERK reactivation and to design
novel therapies that may circumvent this
problem. Paradoxical activation mecha-
nisms have also been proposed to
explain drug resistance acquired in
BRAFV600E mutant melanomas in situa-
tions where a spliced truncated variant
of BRAFV600E lacking a RAS-binding
domain is expressed (Poulikakos et al.,
2011).
Inhibitor-induced ERK pathway activa-
tion in cells expressing BRAFWT requires
RAF dimerization and transactivation pro-
moted by active RAS (Hatzivassiliou et al.,
2010; Heidorn et al., 2010; Poulikakos
et al., 2010). Initial reports proposed that
inhibitor-bound BRAF acts as a scaffold
to enhance CRAF activity at the plasmamembrane following RAS-induced
BRAF-CRAF heterodimer formation.
However, in a separate study, Poulikakos
et al. (2010) demonstrated RAF homo-
dimer and heterodimer formation in
response to inhibitor and proposed a
model whereby inhibitor binding to one
protomer of the RAF homo- or hetero-
dimer leads to its inhibition but causes
transactivation of the other inhibitor-free
protomer. Furthermore, transactivation
was not diminished in BRAF null cells,
highlighting a dominant role of CRAF ho-
modimers. In BRAFV600E tumors, RAS is
inactive and BRAF remains a monomer,
transactivation of RAFWT is not possible,
and inhibition of BRAFV600E becomes
dominant. The importance of dimerization
was supported by analysis of dimerization
mutants (CRAFR401A and BRAFR509H) that
prevented inhibitor-induced transactiva-
tion (Hatzivassiliou et al., 2010). Overall,
these studies led to the hypothesis that
development of non-ATP competitive in-
hibitors that prevent RAF dimerization
would prevent the adverse transactivation
effects.
A novel mechanism involving RAF
autoregulation has now been identified
by Holderfield et al. (2013), in this issue
of Cancer Cell, which changes the thera-
peutic approach significantly. This group
developed nine compounds with varyingl 23, May 13, 2013 ª2013 Elsevier Inc. 561
